Sign In
Buy GLP
$48.63
+0.410 (+0.85%)
At Close: Jul 28, 2026
Albertsons cites slower GLP-1 growth, higher gas prices for a sales miss and downbeat outlook
03:49pm, Tuesday, 14'th Apr 2026
Albertsons's stock was falling Tuesday after a sales miss and an announcement that the grocery-store chain has reached a $774 million settlement to resolve opioid-related claims.
Are Investors Undervaluing Global Partners (GLP) Right Now?
10:40am, Tuesday, 14'th Apr 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Novo Nordisk: Intense Competition Within The GLP-1 Duopoly
10:20am, Tuesday, 14'th Apr 2026
Novo Nordisk reached an all-time high of $148.15 in June 2024, when market participants were widely optimistic about the prospects of NVO's new semaglutide drug for weight management, Wegovy. After a
GLP-1 giant Novo Nordisk partners with OpenAI as pharma industry's AI race accelerates
03:33am, Tuesday, 14'th Apr 2026
The Danish drugmaker becomes the latest major pharmaceutical company to embed AI across its entire drug development pipeline, from discovery to commercial operations. Novo Nordisk (NYSE:NVO), the Dani
Global Partners Announces Cash Distribution on Series B Preferred Units
08:30am, Monday, 13'th Apr 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declare
Novo Nordisk's GLP-1 pill momentum faces pricing test, says leading bank
11:19am, Friday, 10'th Apr 2026
Novo Nordisk (NYSE:NVO) reports first-quarter 2026 results on 6 May, with UBS flagging that the results will provide the first meaningful look at the company's economics at new, lower price points for
16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: M
Amazon Pharmacy to Offer Eli Lilly and Company's New GLP-1 Pill Foundayo via Same-Day Delivery
07:49am, Thursday, 09'th Apr 2026
SEATTLE--(BUSINESS WIRE)--Amazon Pharmacy (NASDAQ: AMZN), a full-service digital pharmacy that offers fast medication delivery directly to customers' homes, now offers Eli Lilly and Company's recently
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.
06:45am, Thursday, 09'th Apr 2026
Foundayo is now available via LillyDirect ® and telehealth providers and is shipping to retail pharmacies nationwide Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day wi
Oral GLP-1 Is Here - Have Credit Markets Caught Up?
02:15am, Thursday, 09'th Apr 2026
For the past two years, GLP-1 medications have been a fixture of consumer trend analysis, discussed by everyone from CNBC to sell-side strategists to management consultants. Real apparel expenditure o
WASHINGTON, April 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the preven
Hims & Hers price target slashed amid GLP-1 transition
12:26pm, Wednesday, 08'th Apr 2026
Bank of America lowered its 2026 price target for Hims & Hers (NYSE:HIMS) to $21 from $23, citing peer multiple compression and near-term earnings pressures. Shares of Hims & Hers traded hands at abou
Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
07:00am, Tuesday, 07'th Apr 2026
Novo Nordisk's new Wegovy GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections. CNBC spoke with five U.S. patie
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
07:00am, Tuesday, 07'th Apr 2026
SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and oth
Kailera Therapeutics Pursues IPO On Promising GLP-1 Trial Results
01:20pm, Monday, 06'th Apr 2026
Kailera Therapeutics is targeting an IPO to fund GLP-1-based obesity treatments, led by ribupatide, with positive efficacy data versus tirzepatide. KLRA is well-capitalized with $546 million in cash,
